Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum

Neuropsychopharmacology

Volumn 26, Issue 3, 2002, Pages 325-339

  Ichikawa, Junji ^a,b   Dai, Jin ^a   O'Laughlin, Ian A ^a   Fowler, Wiley L ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

Acetylcholine release; Medial prefrontal cortex; Nucleus accumbens; Schizophrenia; Striatum; Typical and atypical antipsychotic drugs

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; OXOTREMORINE; RISPERIDONE; SCOPOLAMINE; SULPIRIDE; TETRODOTOXIN; THIORIDAZINE; ZIPRASIDONE;

ACETYLCHOLINE RELEASE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CHOLINERGIC TRANSMISSION; CHOLINESTERASE INHIBITION; COGNITION; CONTROLLED STUDY; CORPUS STRIATUM; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG RECEPTOR BINDING; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CEREBRAL CORTEX; CHOLINESTERASE INHIBITORS; CLOZAPINE; CORPUS STRIATUM; HALOPERIDOL; MALE; NUCLEUS ACCUMBENS; OXOTREMORINE; PIPERAZINES; PIRENZEPINE; RATS; RATS, SPRAGUE-DAWLEY; RISPERIDONE; SCOPOLAMINE; SULPIRIDE; THIAZOLES; THIORIDAZINE;

EID: 0036176263     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00312-8     Document Type: Article

References (101)

1. 1 muscarinic receptors in rat brain using selective muscarinic toxin-1
2. 1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta Stone of antipsychotic drugs
3. Methoctramine moderately improves memory but pirenzepine disrupts performance in delayed non-matching to position test
4. Modulation of cortical in vivo acetylcholine release by the basal nuclear complex: Role of the pontomesencephalic tegmental area
5. Identification of the primary muscarinic autoreceptor subtype in rat striatum as m2 through a correlation of in vivo microdialysis and in vitro receptor binding data
6. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer's disease
7. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in chinese hamster ovary cells
8. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats
9. 1 muscarinic agonist xanomeline (LY246708/NNC11 0232)
10. Radioreceptor binding profile of the atypical antipsychotic olanzapine
11. Xanomeline: A selective muscarinic agonist for the treatment of Alzheimer's disease
12. 1-adrenergic receptors in vitro
13. Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium
14. 1B receptors
15. 1A-mediated facilitation of in vivo acetylcholine release in rat frontal cortex
16. Dopamine in schizophrenia: A review and reconceptualization
17. Dopaminergic-cholinergic interactions in the striatum: The critical significance of calcium concentrations in brain microdialysis
18. 2 dopamine receptor subtypes
19. Estimation of in-vivo neurotransmitter release by brain microdialysis: The issue of validity
20. Central cholinergic systems and cognition
21. 3 muscarinic receptor subtypes in primate brain
22. Pirenzepine for clozapine-induced hypersalivation
23. Demonstration of the facilitatory role of 8-OH-DPAT on cholinergic transmission in the rat hippocampus using in vivo microdialysis
24. 3 receptor preferring antagonists differentially affect striatal dopamine release and metabolism in conscious rats
25. Functional and anatomical aspects of prefrontal pathology in schizophrenia
26. 2 adrenoceptor blockade
27. Serotonergic regulation of acetylcholine release in rat frontal cortex
28. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs
29. 1A receptors on antipsychotic drug induced dopamine release in rat striatum and nucleus accumbens
30. Acetylcholinesterase inhibitors are neither necessary nor desirable for microdialysis studies of brain acetylcholine
31. 1A receptor activation: A possible mechanism of atypical antipsychotic-induced cortical dopamine release
32. 2 receptors on striatal acetylcholine release in rats
33. 1 receptors
34. 1 receptors and their desensitization after chronic treatment
35. Neural systems for behavioral activation and reward
36. Striatal interneurones: Chemical, physiological and morphological characterization
37. Effects of the centrally acting cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats
38. The effect of neuroleptics on cognitive and psychomotor function
39. Antisense oligodeoxynucleotides against the muscarinic m2, but not m4, receptor supports its role as autoreceptors in the rat hippocampus
40. 1A receptor-mediated pathways by BAYx3702 in freely moving rats
41. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens
42. In vivo regulation of acetylcholine release via adenosine a1 receptor in rat cerebral cortex
43. Efficacy and extrapyramidal side effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials
44. Effect of choline on basal and stimulated acetylcholine release: An in vivo microdialysis study using a low neostigmine concentration
45. 1B receptors mediating inhibition of acetylcholine release
46. 1 agonist improves delayed nonmatching to position choice accuracy in rats with cholinergic lesions
47. A double-blind crossover comparison of antiparkinson drug therapy: Amantadine versus anticholinergics in 90 normal volunteers, with an emphasis on differential effects on memory function
48. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values
49. Effect of scopolamine on the efflux of dopamine and its metabolites after clozapine, haloperidol or thioridazine
50. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
51. The role of serotonin in antipsychotic drug action
52. 4 subtypes of muscarinic receptors
53. Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release
54. Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland
55. Cholinergic synaptic circuitry in the macaque prefrontal cortex
56. Effects of oxotremorine and pilocarpine on striatal acetylcholine release as studied by brain dialysis in anesthetized rats
57. 35S]GTPγS
58. Comparative antidiopaminergic properties of thioridazine, mesoridazine and sulforidazine on the corpus striatum
59. Comparative anticholinergic properties of thioridazine, mesoridazine and sulforidazine
60. 1 muscarinic receptor agonist on the central cholinergic system, evaluated by brain microdialysis
61. Effects of clozapine on rat striatal muscarinic receptors coupled to inhibition of adenylyl cyclase activity and on the human cloned m4 receptor
62. Heterogeneity of muscarinic autoreceptors and heteroreceptors in the rat brain: Effects of a novel M1 agonist, AF102B
63. Acute versus chronic haloperidol: Relationship between tolerance to catalepsy and striatal and accumbens dopamine, GABA and acetylcholine release
64. Effects of apomorphine on in vivo release of dopamine and its metabolites in the prefrontal cortex and the striatum, studied by a microdialysis method
65. Selective action of acute systemic clozapine on acetylcholine release in the rat prefrontal cortex by reference to the nucleus accumbens and striatum
66. Acetylcholine in mind: A neurotransmitter correlate of consciousness?
67. Different effects of scopolamine on extracellular acetylcholine levels in neostriatum and nucleus accumbens measured in vivo: Possible interaction with aversive stimulation
68. Antidepressant usage in schizophrenia
69. Galanin stimulates striatal acetylcholine release via a mechanism unrelated to cholinergic receptor stimulation
70. Cognitive improvement in schizophrenia with novel antipsychotic medications
71. Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats
72. In vivo modulation of acetylcholine in the nucleus accumbens of freely moving rats. I. Inhibition by serotonin
73. Regulation of dopamine release and metabolism in rat striatum in vivo: Effects of dopamine receptor antagonists
74. 1 muscarinic receptor antagonists disrupt memory consolidation of inhibitory avoidance in rats
75. 1A receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex
76. 1C receptors
77. Peripherally injected scopolamine differentially modulates acetylcholine release in vivo in the young and aged rats
78. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding
79. 1 receptors
80. 4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice
81. 1A receptor agonist, facilitates cortical acetylcholine release by a mechanism different from that of 8-OH-DPAT in awake rats
82. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia
83. 1 agonist dihydrexidine releases acetylcholine and improves cognitive performance in rats
84. 1 receptor stimulation: Involvement of enhanced nitric oxide production via neurokinin-2 receptor activation
85. 2 antagonists on in vivo hippocampal acetylcholine levels
86. Characterization of the neurochemical effects of N-[2-(1-azabicyclo[3,3,0]octan-5-yl)ethyl]2-nitroaniline fumarate (SK-946) as a cognition activator
87. 2 receptors
88. Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential?
89. Effect of anticholinergics on positive and negative symptoms in schizophrenia
90. Cholinergic aspects of schizophrenia
91. Acetylcholine release in the rat prefrontal cortex in vivo: Modulation by alpha2-adrenoceptor agonists and antagonists
92. L-DOPA inhibits spontaneous acetylcholine release from the striatum of experimental Parkinson's model rats
93. Selective muscarinic antagonists differentially affect in vivo acetylcholine release and memory performances of young and aged rats
94. Dopamine-acetylcholine interaction in the striatum studied by microdialysis in the awake rat: Some methodological aspects
95. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum
96. Essential role of neocortical acetylcholine in spatial memory
97. 4 receptor involvement in the enhancement of acetylcholine release by p-chloroamphetamine in rat frontal cortex
98. 4 receptors
99. Muscarinic m4 receptor activation by some atypical antipsychotic drugs
100. 4 receptor agonist